COVIRIX Medical Pty Ltd is an Australia-based biopharmaceutical company focused on developing small‑molecule antiviral therapeutics. Its programs target a range of respiratory and other viruses with pandemic potential, aiming to deliver broad‑spectrum activity suitable for rapid deployment in outbreak settings.
The company’s work spans discovery chemistry, virology, and formulation through preclinical development, with an emphasis on advancing candidates efficiently toward clinical evaluation. COVIRIX collaborates with academic and industry partners to assess delivery approaches and accelerate product development. Its activities sit at the intersection of pharmaceuticals and the chemical industry, encompassing the design and optimization of antiviral active ingredients and their dosage forms.
